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ABSTRACT
Objective: To examine a large UK cohort of patients
with postural tachycardia syndrome (PoTS), to
compare demographic characteristics, symptoms and
treatment of PoTS at one centre compared to the
largest patient group PoTS UK and to verify if their
functional limitation is similar to patients with chronic
fatigue syndrome (CFS).
Design: A cross-sectional study assessed the
frequency of symptoms and their associated variables.
Patients and setting: Two PoTS cohorts were: (1)
recruited via PoTS UK, (2) diagnosed at Newcastle
Hospitals National Health Service (NHS) Foundation
Trust 2009–2012. Patients with PoTS were then
compared to a matched cohort with CFS.
Main outcome measures: Patients’ detailed
demographics, time to diagnosis, education, disability,
medications, comorbidity and precipitants. Symptom
assessment tools captured, Fatigue Impact Scale,
Epworth Sleepiness Scale, Orthostatic Grading Scale
(OGS), Hospital Anxiety and Depression Scale, Health
Assessment Questionnaire, Cognitive Failures
Questionnaire.
Results: 136 patients with PoTS participated (84
members of PoTS UK (170 cohort; 50% return) and
52 (87 cohort; 60%) from Newcastle Clinics). The
PoTS UK population was significantly younger than the
clinic patients, with significantly fewer men (p=0.005).
Over 60% had a university or postgraduate degree.
Significantly more of the PoTS UK cohort were
working, with hours worked being significantly higher
(p=0.001). Time to diagnosis was significantly longer
in the PoTS UK cohort (p=0.04). Symptom severity
was comparable between cohorts. The PoTS total
group was compared with a matched CFS cohort;
despite comparable levels of fatigue and sleepiness,
autonomic symptom burden (OGS) was statistically
significantly higher. The most common treatment
regime included β-blockers. Overall, 21 treatment
combinations were described. Up to 1/3 were taking no
treatment.
Conclusions: Patients with PoTS are predominantly
women, young, well educated and have significant and
debilitating symptoms that impact significantly on
quality of life. Despite this, there is no consistent
treatment.
INTRODUCTION
Postural tachycardia syndrome (PoTS) is a
subset of orthostatic intolerance that is asso-
ciated with the presence of excessive tachy-
cardia on standing. Symptoms may be so
severe that normal activities of life, such as
bathing, housework and even eating, can be
significantly limited.1 Patients with PoTS
have been reported to suffer from a degree
of functional impairment similar to that seen
in conditions such as chronic obstructive pul-
monary disease and congestive heart failure;
yet these patients are frequently misdiag-
nosed as having severe anxiety, panic dis-
order or chronic fatigue syndrome (CFS)
because of a lack of awareness of the condi-
tion and its functional impact by healthcare
professionals.2
Studies performed in the USA suggest that
PoTS affects approximately 170/100 000 of
the population, and of this total, 25% are dis-
abled and unable to work. PoTS can affect
any age group, but predominantly presents
in young and middle age groups.3 No such
studies currently exist from the UK.
Strengths and limitations of this study
▪ Description of the demographics and symptom
burden experienced by a large cohort of patients
with positional tachycardia syndrome.
▪ Cross-sectional ‘opt in’ study using self-report
symptom assessment tools.
▪ Study performed in collaboration with the
national PoTS patient support group.
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The principal feature of PoTS is orthostatic intoler-
ance. This is defined as the provocation of symptoms on
standing that are relieved by lying down.4 Those with
PoTS frequently present with palpitations, fatigue, light-
headedness, exercise intolerance, nausea, diminished
concentration, tremulousness, syncope and presyncope.5
In adults, PoTS is currently defined as the presence of
symptoms of orthostatic intolerance associated with a
heart rate increase of 30 bpm (or a rate that exceeds
120 bpm) that occurs within the first 10 min of standing
or upright tilt, not associated with other chronic debili-
tating conditions such as prolonged bed rest or the use
of medications known to diminish vascular or autonomic
tone.6 In teenagers, the criteria suggest that an increase
in 40 bpm on standing is diagnostic.7 The aim of this
current study was twofold. First, we wanted to raise
awareness of the prevalence and impact of PoTS in
healthcare professionals by collating a large cohort of
patients with PoTS in the UK. Second, we wanted to see
whether there were differences between patients with
PoTS seen in one centre compared with members of the
largest patient support group PoTS UK who provide
support exclusively for patients with PoTS.
METHODS
Patients
Postural tachycardia syndrome
Two cohorts of patients with PoTS were included in this
study; the first cohort was recruited via the national
patient support group PoTS UK (http://www.potsuk.
org.uk) and the second cohort was made up of all those
diagnosed with PoTS at the Falls and Syncope Service
Newcastle upon Tyne Hospitals National Health Service
(NHS) Foundation Trust between May 2009 and April
2012. Both cohorts included only patients where a diag-
nosis had been reached by a secondary care clinician.
PoTS UK is an independent UK registered small charity.
People join PoTS UK after finding the website through
search engines or links from other websites. At the time
of this study, PoTS UK had 170 members. The Newcastle
Clinic Cohort comprised 87 patients with PoTS.
Patients with CFS
Patients with CFS were consecutive patients referred to
the Newcastle Royal Victoria Infirmary who fulfilled the
Fukuda 1994 diagnostic criteria for CFS8 who had been
shown on haemodynamic testing to not have PoTS.
Symptom assessment tools
The complete survey form was developed in two parts.
The first part contained questions about demographics,
age since symptoms began and age at diagnosis, educa-
tion, disability, medications and symptoms at the time of
completing the survey. Next were questions about
characteristics of PoTS including comorbidity and poten-
tial precipitants. Following these, participants completed
six validated symptom assessment tools quantifying
fatigue, daytime sleepiness, orthostatic symptoms,
anxiety and depressive symptoms, functional ability and
cognitive failures.
Fatigue Impact Scale
The Fatigue Impact Scale (FIS) assesses perceptions of
how fatigue affects cognitive, physical and psychosocial
functions. It is validated for self-completion and used in
a number of fatigue-associated diseases9–13 and CFS.13 It
comprises 40 items; participants rate how these items
are affected by fatigue on a five-point scale: 0 (no
problem) to 4 (extreme problem). Total score is calcu-
lated by adding responses from the 40 questions; pos-
sible range 0–160.
Epworth Sleepiness Scale
A validated self-report assessment tool that quantifies
symptoms of daytime sleepiness.14 Consists of eight
items, each graded 0–3. Higher scores indicate a greater
impact of daytime sleepiness.
Orthostatic Grading Scale
Quantifies the symptoms of orthostatic intolerance due
to hypotension, with questions related to frequency and
severity of symptoms and interference with daily activ-
ities.15 It consists of five items, each graded on a scale of
0–4. Higher scores indicate a greater impact of ortho-
static symptoms.
Hospital Anxiety and Depression Scale
A validated anxiety and depression measure optimised
for use in patients with chronic disease.16 Individual sub-
scales comprise seven items, each with a potential score
0–21. For the purposes of this study, ‘caseness’ for
depression or anxiety was defined as a score of 11 or
greater for the subscale.
Patient-Reported Outcomes Measurement Information
System, Health Assessment Questionnaire (PHAQ)
Assesses the functional and physical ability of partici-
pants.17 The PHAQ consists of 20 items that ask patients
to rate their ability to carry out daily activities on a five-
point scale of ‘0=without any difficulty’ to ‘4=unable to
do’. Higher scores indicate a worse functional ability
and therefore greater functional impairment.
Cognitive Failures Questionnaire
Assesses cognitive symptom prevalence by measuring the
frequency of cognitive slips or failures occurring in
everyday life.18 Consists of 25 items covering failures in
perception, memory and motor function and asks
patients to rate how often these failures occur, on a five-
point Likert scale 0–4 (0=never, 4=very often). The
responses for the 25 questions are added together to
obtain the total Cognitive Failures Questionnaire (CFQ)
score. The higher the score, the greater the cognitive
impairment.
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Study design
We used a cross-sectional study design to assess the fre-
quency of symptoms and their associated variables at a
single point in time. The same survey was sent to all
members of PoTS UK and PoTS clinic patients in 2012.
Patients who were 16 years old or older were requested
to complete and return the survey. For the PoTS UK
cohort, surveys were emailed by PoTS UK to all
members. The survey was featured on the PoTS UK
website and in the newsletter. No participant identifiable
information was provided to the investigators, and there-
fore no written consent was obtained from participants
but return of the anonymous questionnaires was consid-
ered as implied consent for the use of the data. For the
PoTS clinic cohort, surveys were mailed to all patients
who had been diagnosed with PoTS. To increase
response, surveys were mailed one additional time to
those who had not returned the initial survey within
4 weeks. Patients in the Falls and Syncope Service
provide written informed consent agreeing that they are
happy to participate in research, audit and service evalu-
ation. Results of the symptom assessment tools were
compared with those completed by a cohort of matched
patients with CFS attending our clinic.
Analysis
All analyses were carried out using statistical software
(GraphPad, Prism V.5). Descriptive statistics for each of
the analysed parameters were initially calculated separ-
ately for the PoTS UK and the clinic cohorts. For con-
tinuous parameters, either median and range, or mean
and SE, were calculated; for categorical variables, per-
centages were calculated.
RESULTS
Response rates
A total of 136 patients with PoTS completed and
returned the questionnaires. This comprised 84
members of PoTS UK (170 cohort; 50% return) and 52
(87 cohort; 60%)) patients with PoTS attending the Falls
and Syncope Service.
Demographics of the two groups
The PoTS UK population was significantly younger than
the PoTS clinic patients, with significantly fewer men
(p=0.005; table 1). Interestingly, there were proportion-
ately more smokers in the PoTS UK group but relatively
similar proportions drinking alcohol and taking caffeine.
There were, however, four in the PoTS UK population
(5%) compared to none in the PoTS clinic cohort who
were taking recreational drugs specifically stated to be
cannabis. On reviewing the educational level of both
cohorts, it became clear that, taken together, patients
with PoTS are well educated, with over 60% of the popu-
lation having either a university or a postgraduate
degree. This was comparable between the two cohorts.
Significantly more of the PoTS UK cohort were working
and when they were working, the hours that they were
able to work were significantly higher (p=0.001).
Despite this, a large proportion of the patients with
PoTS had to change their job because of ill health and
had been unable to work because of problems with their
health.
Overall symptom burden of the groups
Symptoms started at a significantly younger age in the
PoTS UK cohort (23 vs 28 years of age) and diagnosis
age was not significantly different with the PoTS UK
population being diagnosed on average at the age of 30
compared with 33 in the PoTS clinic cohort. As a conse-
quence, time to diagnosis after the onset of symptoms
was significantly longer in the PoTS UK population com-
pared with the group attending a specialist clinic
(p=0.04). When considering the symptom assessment
tools completed by participants with PoTS, there were
no significant differences in symptom severity between
the PoTS UK cohort and PoTS clinic cohort, with high
levels of fatigue, daytime sleepiness, orthostatic symp-
toms, anxiety and depression, particularly high levels of
functional impairment and cognitive symptoms.
Around 20% of the total cohort reported having CFS
and just under 20% had Ehlers-Danlos syndrome, but
when we considered the PoTS UK population compared
with the PoTS clinic cohort, this showed some interest-
ing differences, with the PoTS clinic cohort having 42%
of the cohort with comorbid CFS/myalgic encephalomy-
elitis (ME) compared with 26% of the PoTS UK having
comorbid Ehlers-Danlos syndrome (EDS; table 1).
Comparing the total PoTS group to a matched CFS group
In view of the fact that the PoTS UK and the PoTS clinic
cohort were comparable in terms of symptom severity,
we considered the total group (n=136) and compared
this to an age-matched and sex-matched cohort of
patients with CFS. The CFS group had a mean±SD age
of 36±10 years (p=ns). Interestingly, despite comparable
levels of symptom burden measured by the FIS and
daytime sleepiness measured by the Epworth Sleepiness
Scale, the scores from the Orthostatic Grading Scale
(OGS; autonomic symptom burden) were statistically sig-
nificantly higher in the PoTS group compared with the
CFS group. Hospital Anxiety and Depression Scale
(HADS) scores were significantly higher in the CFS
group despite high levels of symptoms in both groups
(figure 1).
Comparing the symptom burden of patients with PoTS
with and without comorbid CFS/ME
We went on to consider the total PoTS cohort of 136
patients and compared those with (n=27) and without
(n=109) comorbid CFS. When we considered the
number of symptoms that they first noticed before being
diagnosed with PoTS, those without CFS had significantly
more symptoms (p=0.0004), with the majority of these
symptoms being palpitations, dizziness, memory
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impairment, breathlessness, light-headedness and muscle
aches. Twenty-three (21%) of the patients with PoTS and
without CFS were currently receiving disability benefit
compared with 13 (48%) of the patients with PoTS and
CFS (table 2). The participants with PoTS with no CFS
appeared to be more able to exercise, with 44% of the
patients with PoTS with no CFS currently engaging in any
form of exercise compared with 29% of the patients with
PoTS and with CFS. In those who were not exercising, the
vast majority in both groups felt that this was because of
fatigue or because they knew it would worsen their symp-
toms. In terms of hours that they had spent performing
activities, there was no significant difference between
patients with PoTS with and without CFS in terms of
household-related activities, social and recreational activ-
ities and family-related activities; however, the PoTS
without CFS group did appear to have spent significantly
more hours in work-related activities. Interestingly, 34%
of the PoTS without CFS group had spontaneously
reported episodes of loss of consciousness in association
with their symptoms compared with 18% of the PoTS
with CFS group. When we reviewed symptoms in the two
groups that would be consistent with the diagnosis of CFS
(Fukuda), of patients with PoTS who did not describe
comorbid CFS, 43% of them would actually have met the
diagnostic criteria for CFS. The vast majority of patients
with PoTS had noticed an infection as the precipitating
cause for their symptoms, and interestingly, six of the
PoTS without CFS group (seven in total) did not describe
themselves as being ill at all. Scores from the symptom
assessment tools confirmed that those with PoTS with
and without CFS had higher levels of orthostatic intoler-
ance measured using the OGS compared with the CFS
group (figure 2).
The impact of treatments
The treatments that patients with PoTS were using are
shown in table 3. The most common treatment, either
alone or in combination, was β-blockers. Overall, there
was a wide range of different therapies being used with
21 different combinations described by patients with
PoTS. In total, 26.5% of patients in PoTS UK and 34.5%
Table 1 Demographics of the PoTS UK cohort compared with the PoTS clinic cohort
PoTS UK PoTS clinic p Value Total PoTS
N 84 52 136
Age, mean±SD 32±10 36±11 0.04 33±10
Males, n (%) 3 (4) 10 (19) 0.005 13 (10)
BMI, mean±SD 24±5 34±5 0.09 27±5
Smokers, n (%) 12 (14) 2 (4) 0.08 14 (10)
Previous smoker, n (%) 14 (17) 6 (12) 0.5 20 (15)
Alcohol, yes, n (%) 28 (33) 20 (38) 0.6 48 (35)
Caffeine, yes, n (%) 46 (55) 34 (65) 0.3 80 (59)
Drugs, yes, n (%) 4 (5) 0 0.3 4 (3)
Age symptoms started, mean±SD 23±10 n=76 28±12 n=50 0.01 24±11
Age diagnosed, mean±SD 30±10 n=82 33±11 n=48 0.09 31±10
Difference, mean±SD 8.3±10 n=79 5.2±5 n=49 0.04 6.7±7
Symptoms assessment tools
Fatigue Impact Scale 91±32 92±37 0.8 92±34
Epworth Sleepiness Scale 10±5 10±8 0.8 10±5
Orthostatic Grading Scale 13±4 12±4 0.4 13±4
Hospital Anxiety and Depression 14±7 15±9 0.3 15±7
Patient Reported Outcome Measure Health
Assessment Questionnaire
26±21 26±22 1.0 26±21
Cognitive Failures Questionnaire 50±24 51±23 0.7 51±23
Comorbidity
Chronic Fatigue Syndrome 6 (7) 22 (42) 0.0001 28 (21)
Ehlers Danlos Syndrome 22 (26) 2 (4) 0.0009 24 (18)
Irritable Bowel Syndrome 9 (11) 5 (10) 1.0 14 (10)
Thyroid 10 (12) 3 (6) 0.4 13 (10)
Heart 4 (5) 0 0.3 4 (3)
Fibromyalgia 7 (8) 2 (4) 0.5 9 (7)
Education
Left school at 16 9 (11) 12 (23) 0.09 21 (15)
Left school at 18 7 (8) 5 (10) 1.0 12 (9)
University degree 33 (40) 23 (44) 0.6 56 (41)
Postgraduate degree 16 (19) 12 (23) 0.7 28 (21)
Other 14 (17) 0 14 (10)
BMI, body mass index.
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Figure 1 Symptom assessment
tools in the total postural
tachycardia syndrome (PoTS)
group compared with the
age-matched and sex-matched
chronic fatigue syndrome (CFS)
group. Autonomic symptom
burden and scores from Hospital
Anxiety and Depression Scale are
higher in the PoTS group
compared with the CFS group
while fatigue and daytime
sleepiness are comparable.
Table 2 Comparison between the postural tachycardia syndrome (PoTS) with comorbid chronic fatigue syndrome (CFS) and
PoTS without comorbid CFS
PoTS
No CFS
PoTS
With CFS p Value
N 109 27
Proportion working n (%) 57 (52) 11 (41) 0.4
When working hours worked (median (IQR)) 30 (26–33) 5 (0.2–23) 0.001
Symptoms described
by patients with PoTS
Number of symptoms first noticed (median (IQR)) 2 (2.3–2.9) 1 (1.1–2.3) 0.0004
Palpitations n (%) 80 (73) 16 (60) 0.9
Fatigue n (%) 85 (78) 24 (89)
Dizziness n (%) 87 (80) 20 (74)
Memory n (%) 47 (43) 13 (48)
Breathlessness n (%) 63 (58) 14 (52)
Light-headedness n (%) 89 (82) 20 (74)
Muscle aches n (%) 54 (50) 16 (59)
Are you currently engaging in any form of exercise? n (%) 48/109 (44) 8/27 (30) 0.2
If you do not exercise,
why do you not
exercise?
n (%)
Not interested 1/61 (2) 0/20 1.0
No time 7/61 (12) 0/20
Would like to but cannot because of fatigue 46/61 (75) 16/20 (80)
Cannot because symptoms worsen 49/61 (80) 17/20 (85)
In the past 4 weeks,
how many hours have
you spent (median
hours/week (IQR))
Household-related activities 5 (6–11) 4 (4–16) 0.5
Social and recreational activities 4 (4–7) 4 (3–7) 0.8
Family-related activities 5 (6–13) 5 (4–12) 1.0
Work-related activities 3 (11–20) 0 (0.8–12) 0.04
Other symptoms (n
(%))
Reports LOC or presyncope 37/109 (34) 5/27 (19) 0.2
Symptoms consistent with CFS 47/109 (43) 20/27 (74) 0.005
Onset (n (%)) Infection 35/109 (32) 16/27 (59) 0.05
Accident 14/109 (13) 1/27 (4)
Holiday 7/109 (6) 1/27 (4)
Immunisation 6/109 (6) 7/27 (26)
Surgery 10/109 (9) 4/27 (15)
Severe stress 24/109 (22) 8/27 (30)
Other 34/109 (31) 5/27 (19)
I am not ill 6/109 (6) 1/27 (4)
LOC, loss of consciousness.
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in the PoTS clinic cohort were taking no treatment or
only salt for their PoTS. When we compared those
taking medication to those not, there were no significant
differences in fatigue severity, daytime sleepiness, cogni-
tive or autonomic symptom burden, and nor was the
level of functional impairment different (data not
shown). Those taking no medication did, however, score
higher on HADS compared with those taking medica-
tion (mean±SD HAD 17±8 vs 14±7; p=0.01).
DISCUSSION
In this study, we have explored for the first time the
characteristics of patients with PoTS in the UK using a
clinic-based cohort and a population obtained via a
national patient support group. We have shown that
patients with PoTS are predominantly women, young,
well educated and have significant and debilitating symp-
toms that impact significantly on their quality of life.
Despite this, there is no consistent treatment, high levels
of disability and associated comorbidity.
Importantly for patients, we found that although indi-
viduals presented with symptoms at the same age, those
attending a specialist clinic received a diagnosis quicker.
We would suggest that this advocates the need for spe-
cialist care for those with PoTS to reduce the overall
impact of the condition. The average age of diagnosis
was young; however, there was a wide age range with the
oldest patients with PoTS presenting at age 63. It is
therefore vital that the symptoms are recognised, taken
seriously and treated early.
The differences between a cohort from one clinic and
the national patient support service were interesting.
Most of the current PoTS literature comes from one or
more specialist referral clinics. The data from our survey
reflect the broader population with PoTS and may there-
fore be different from the experiences that are usually
reported in the literature.
The symptom burden for those with PoTS is high and
we have shown it to be comparable to that seen in CFS.
CFS is a chronic condition that is recognised by the
WHO as a neurological disorder and by the Disability
Discrimination Act 2005 as a disability.19 We would
suggest that our data highlight that at the current time
those with PoTS suffer to the same extent as those with
CFS but do not receive the same protection from the
law. Our study confirming that patients with PoTS had
even higher autonomic symptom scores measured using
the OGS might explain in part the high prevalence of
dysautonomia in unselected cohorts of patients with
CFS.20–22 It is important that more work is carried out to
understand the underlying autonomic abnormality in
those with PoTS in order to allow us to develop targeted
treatments that are effective and go beyond the currently
available simply symptomatic management.
Our finding of high levels of comorbidity, particularly
CFS and EDS, is important as it might point towards an
underlying overlapping mechanism.23–25 We believe that
more work is needed to understand this spectrum of dis-
eases and whether lessons could be learnt from one
disease that could be applied to others. It is possible
that the higher prevalence of CFS reported in the PoTS
clinic cohort reflects the research interests of the clin-
ician and therefore a referral bias. However, the lower
prevalence of EDS in the clinic cohort has highlighted
important training needs for the Newcastle clinicians
and it will be interesting to explore in the future
whether the prevalence rates of EDS in patients with
PoTS attending the Newcastle clinic increase.
Figure 2 Orthostatic Grading Scale scores in the postural
tachycardia syndrome (PoTS) group with comorbid chronic
fatigue syndrome (CFS; PoTS +) and PoTS without comorbid
CFS (PoTS −) are significantly higher compared with the
group with CFS.
Table 3 Medications used by patients with postural
tachycardia syndrome (PoTS)
Primary
treatment Combination PoTS UK
PoTS
clinic
No treatment 20 (24%) 17 (32.5%)
β-blocker Alone 15 (18%) 10 (19%)
Plus midodrine 4 (5%) 2 (4%)
Ivabradine Alone 4 (5%) 7 (13%)
Midodrine 0 2 (4%)
Fludrocortisone 1 (1%) 1 (2%)
Sertraline 1 (1%) 0
Duloxetine 1 (1%) 0
β-blocker 0 1 (2%)
Diltiazem Alone 1 (2%)
Fludrocortisone 1 (1%) 0
Midodrine 0 1 (2%)
Verapamil Alone 0 1 (2%)
Fludrocortisone Alone 5 (6%) 2 (4%)
β-blocker 5 (6%) 2 (4%)
Midodrine 5 (6%) 0
Midodrine Alone 12 (14%) 4 (7.5%)
Buproprion 1 (1%) 0
Octretide + midodrine
+ fludro
2 (2.5%) 0
Pregabalin 1 (1%) 0
Clonazepam 1 (1%) 0
Antidepressant 3 (4%) 0
Salt only 2 (2.5%) 1 (2%)
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This study has a number of limitations. The preva-
lence of CFS and EDS was determined by self-report and
therefore could be considered to be unreliable. Further
studies are needed that involve clinical characterisation
of patients with PoTS to determine directly whether self-
reports are accurate. The response rates were low, par-
ticularly from the patients’ support group PoTS UK,
something which was surprising considering the lack of
research and evidence with this group of patients and
the strong desire for a greater understanding. It is pos-
sible that the membership of PoTS UK, which is in
excess of 170, is comprised of sufferers but also carers
and relatives.
Interestingly, 24% of patients with PoTS from PoTS
UK and 33% of the clinic cohort were taking no medica-
tion for their PoTS. This was a surprise to us and we
would suggest that it is an important observation for
clinicians managing patients, that is, medication might
not always be the answer, but it might also be that the
current available treatments are associated with high
levels of unacceptable side effects that are not tolerated
by patients with PoTS. This, together with the 21 differ-
ent treatment regimes described, strongly underlines the
need for more evidence regarding treatments in PoTS
and the urgent need for randomised controlled trials.
This is similar to the findings from the largest published
US series from the Mayo Clinic.26 The most frequently
used medication appears to be β-blockers, which provide
symptomatic control of the heart rate. With a better
understanding of the characteristics of patients with
PoTS and the associated comorbidity and autonomic
abnormalities present on objective testing, it is hoped
that better treatments can be developed. These treat-
ments will need to not only provide symptomatic relief
but also look at reducing the perpetuation of symptoms
on those affected acutely and perhaps even stopping
establishment of PoTS after the acute precipitating
event.
It is becoming increasingly clear that historically many
patients with PoTS were given a diagnosis of CFS/ME. A
recent cross-sectional study performed by us has con-
firmed that 27% of those with a diagnosis of CFS have
PoTS.27 This is important when the public health impli-
cations of CFS/ME, and fatigue in its more general
sense, are considered.
At present, only limited data are available on the prog-
nosis of patients with PoTS. One recent retrospective
study has suggested that the outcome is benign,28
although we would argue that our study suggests that the
effects that PoTS has for individuals affected is far from
benign and is associated with considerable morbidity.
Our experience suggests that some patients never
recover, and that a subset will worsen over time.
In conclusion, PoTS is a condition that is associated
with significant symptoms that impact on quality of life.
Currently, there are no evidence-based treatments for
PoTS, and its underlying pathogenesis, natural history
and associated features are not fully understood. We
would suggest that increasing awareness of this debilitat-
ing disease is important to improve understanding, diag-
nosis and management of PoTS.
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affecting young women: a UK perspective
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associated with significant symptoms and 
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